PSPriyanka Sharma

Priyanka Sharma

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Priyanka Sharma has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Figures 1-8 from Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) Overcomes Adaptive Drug Resistance in Acute Myelogenous Leukemia

    by Seemana Bhattacharya, Sujan Piya, Huaxian Ma, Priyanka Sharma, Qi Zhang, Natalia Baran, Vivian R. Ruvolo, Teresa McQueen, R. Eric Davis, Rasoul Pourebrahim, et al.

    S1. Effect of genetic abrogation of ULK1 in vitro and in vivo.S2. ULK1 inhibitor SBI-0206965 has anti-leukemic activity and can overcome autophagic adaptation in drug-resistant cells.S3. ULK1 inhibition reverses drug-resistance and synergizes with AML therapies.S4. ULK1 inhibition changes signaling in AML cells.S5. ULK1 inhibition hampers ROS.S6. ULK1 inhibition accumulates dysfunctional mitochondria.S7. ULK1 inhibition impairs colony forming ability and delays leukemia progression.S8. In vitro and in vivo synergy of ULK1 inhibition with AML therapies.

  • Open Access

    Supplementary Tables 1-9 from Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) Overcomes Adaptive Drug Resistance in Acute Myelogenous Leukemia

    by Seemana Bhattacharya, Sujan Piya, Huaxian Ma, Priyanka Sharma, Qi Zhang, Natalia Baran, Vivian R. Ruvolo, Teresa McQueen, R. Eric Davis, Rasoul Pourebrahim, et al.

    Supplementary Table S1. Abbreviations of cell populations analyzed using Bloodspot.Supplementary Table S2. Comparative analysis of significance based on survival curves generated using GraphPad.Supplementary Table S3. Mutational profiles of AML cell lines and their sensitivity to SBI-0206965.Supplementary Table S4. Mutational profiles of AML patient derived primary samples.Supplementary Table S5. IC50 values of drug resistant cells.Supplementary Table S6. Combinatorial Index (CI-value) of combination treatments.Supplementary Table S7. Comparative analysis of significance based on survival curves generated using GraphPad (Ex vivo model).Supplementary Table S8. List of Antibodies.Supplementary Table S9. List of Primers.

  • Open Access

    Targeting metabolic vulnerabilities to overcome resistance to therapy in acute myeloid leukemia

    by Priyanka Sharma, Gautam Borthakur

    Malignant hematopoietic cells gain metabolic plasticity, reorganize anabolic mechanisms to improve anabolic output and prevent oxidative damage, and bypass cell cycle checkpoints, eventually outcompeting normal hematopoietic cells. Current therapeutic strategies of acute myeloid leukemia (AML) are based on prognostic stratification that includes mutation profile as the closest surrogate to disease biology. Clinical efficacy of targeted therapies, e.g., agents targeting mutant FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1 or 2, are mostly limited to the presence of relevant mutations. Recent studies have not only demonstrated that specific mutations in AML create metabolic vulnerabilities but also highlighted the efficacy of targeting metabolic vulnerabilities in combination with inhibitors of these mutations. Therefore, delineating the functional relationships between genetic stratification, metabolic dependencies, and response to specific inhibitors of these vulnerabilities is crucial for identifying more effective therapeutic regimens, understanding resistance mechanisms, and identifying early response markers, ultimately improving the likelihood of cure. In addition, metabolic changes occurring in the tumor microenvironment have also been reported as therapeutic targets. The metabolic profiles of leukemia stem cells (LSCs) differ, and relapsed/refractory LSCs switch to alternative metabolic pathways, fueling oxidative phosphorylation (OXPHOS), rendering them therapeutically resistant. In this review, we discuss the role of cancer metabolic pathways that contribute to the metabolic plasticity of AML and confer resistance to standard therapy; we also highlight the latest promising developments in the field in translating these important findings to the clinic and discuss the tumor microenvironment that supports metabolic plasticity and interplay with AML cells.


  • Open Access

    Supplementary Tables 1-9 from Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) Overcomes Adaptive Drug Resistance in Acute Myelogenous Leukemia

    by Seemana Bhattacharya, Sujan Piya, Huaxian Ma, Priyanka Sharma, Qi Zhang, Natalia Baran, Vivian R. Ruvolo, Teresa McQueen, R. Eric Davis, Rasoul Pourebrahim, et al.

    Supplementary Table S1. Abbreviations of cell populations analyzed using Bloodspot.Supplementary Table S2. Comparative analysis of significance based on survival curves generated using GraphPad.Supplementary Table S3. Mutational profiles of AML cell lines and their sensitivity to SBI-0206965.Supplementary Table S4. Mutational profiles of AML patient derived primary samples.Supplementary Table S5. IC50 values of drug resistant cells.Supplementary Table S6. Combinatorial Index (CI-value) of combination treatments.Supplementary Table S7. Comparative analysis of significance based on survival curves generated using GraphPad (Ex vivo model).Supplementary Table S8. List of Antibodies.Supplementary Table S9. List of Primers.

  • Open Access

    Supplementary Figures 1-8 from Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) Overcomes Adaptive Drug Resistance in Acute Myelogenous Leukemia

    by Seemana Bhattacharya, Sujan Piya, Huaxian Ma, Priyanka Sharma, Qi Zhang, Natalia Baran, Vivian R. Ruvolo, Teresa McQueen, R. Eric Davis, Rasoul Pourebrahim, et al.

    S1. Effect of genetic abrogation of ULK1 in vitro and in vivo.S2. ULK1 inhibitor SBI-0206965 has anti-leukemic activity and can overcome autophagic adaptation in drug-resistant cells.S3. ULK1 inhibition reverses drug-resistance and synergizes with AML therapies.S4. ULK1 inhibition changes signaling in AML cells.S5. ULK1 inhibition hampers ROS.S6. ULK1 inhibition accumulates dysfunctional mitochondria.S7. ULK1 inhibition impairs colony forming ability and delays leukemia progression.S8. In vitro and in vivo synergy of ULK1 inhibition with AML therapies.

  • Open Access

    Supplementary Tables 1-9 from Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) Overcomes Adaptive Drug Resistance in Acute Myelogenous Leukemia

    by Seemana Bhattacharya, Sujan Piya, Huaxian Ma, Priyanka Sharma, Qi Zhang, Natalia Baran, Vivian R. Ruvolo, Teresa McQueen, R. Eric Davis, Rasoul Pourebrahim, et al.

    Supplementary Table S1. Abbreviations of cell populations analyzed using Bloodspot.Supplementary Table S2. Comparative analysis of significance based on survival curves generated using GraphPad.Supplementary Table S3. Mutational profiles of AML cell lines and their sensitivity to SBI-0206965.Supplementary Table S4. Mutational profiles of AML patient derived primary samples.Supplementary Table S5. IC50 values of drug resistant cells.Supplementary Table S6. Combinatorial Index (CI-value) of combination treatments.Supplementary Table S7. Comparative analysis of significance based on survival curves generated using GraphPad (Ex vivo model).Supplementary Table S8. List of Antibodies.Supplementary Table S9. List of Primers.

  • Open Access

    Supplementary Figures 1-8 from Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) Overcomes Adaptive Drug Resistance in Acute Myelogenous Leukemia

    by Seemana Bhattacharya, Sujan Piya, Huaxian Ma, Priyanka Sharma, Qi Zhang, Natalia Baran, Vivian R. Ruvolo, Teresa McQueen, R. Eric Davis, Rasoul Pourebrahim, et al.

    S1. Effect of genetic abrogation of ULK1 in vitro and in vivo.S2. ULK1 inhibitor SBI-0206965 has anti-leukemic activity and can overcome autophagic adaptation in drug-resistant cells.S3. ULK1 inhibition reverses drug-resistance and synergizes with AML therapies.S4. ULK1 inhibition changes signaling in AML cells.S5. ULK1 inhibition hampers ROS.S6. ULK1 inhibition accumulates dysfunctional mitochondria.S7. ULK1 inhibition impairs colony forming ability and delays leukemia progression.S8. In vitro and in vivo synergy of ULK1 inhibition with AML therapies.

  • Open Access

    Data from Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) Overcomes Adaptive Drug Resistance in Acute Myelogenous Leukemia

    by Seemana Bhattacharya, Sujan Piya, Huaxian Ma, Priyanka Sharma, Qi Zhang, Natalia Baran, Vivian R. Ruvolo, Teresa McQueen, R. Eric Davis, Rasoul Pourebrahim, et al.

    Despite effective new therapies, adaptive resistance remains the main obstacle in acute myelogenous leukemia (AML) therapy. Autophagy induction is a key mechanism for adaptive resistance. Leukemic blasts at diagnosis express higher levels of the apical autophagy kinase ULK1 compared with normal hematopoietic cells. Exposure to chemotherapy and targeted agents upregulate ULK1, hence we hypothesize that developing ULK1 inhibitors may present the unique opportunity for clinical translation of autophagy inhibition. Accordingly, we demonstrate that ULK1 inhibition, by genetic and pharmacologic means, suppresses treatment-induced autophagy, overcomes adaptive drug-resistance, and synergizes with chemotherapy and emerging antileukemia agents like venetoclax (ABT-199). The study next aims at exploring the underlying mechanisms. Mechanistically, ULK1 inhibition downregulates MCL1 antiapoptotic gene, impairs mitochondrial function and downregulates components of the CD44-xCT system, resulting in impaired reactive oxygen species (ROS) mitigation, DNA damage, and apoptosis. For further validation, several mouse models of AML were generated. In these mouse models, ULK1 deficiency impaired leukemic cell homing and engraftment, delayed disease progression, and improved survival. Therefore, in the study, we validated our hypothesis and identified ULK1 as an important mediator of adaptive resistance to therapy and an ideal candidate for combination therapy in AML. Therefore, we propose ULK1 inhibition as a therapeutically relevant treatment option to overcome adaptive drug-resistance in AML.Implications:ULK1 drives a cell-intrinsic adaptive resistance in AML and targeting ULK1-mediated autophagy can synergize with existing and emerging AML therapies to overcome drug-resistance and induce apoptosis.

  • Open Access

    Supplementary Figures 1-8 from Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) Overcomes Adaptive Drug Resistance in Acute Myelogenous Leukemia

    by Seemana Bhattacharya, Sujan Piya, Huaxian Ma, Priyanka Sharma, Qi Zhang, Natalia Baran, Vivian R. Ruvolo, Teresa McQueen, R. Eric Davis, Rasoul Pourebrahim, et al.

    S1. Effect of genetic abrogation of ULK1 in vitro and in vivo. S2. ULK1 inhibitor SBI-0206965 has anti-leukemic activity and can overcome autophagic adaptation in drug-resistant cells. S3. ULK1 inhibition reverses drug-resistance and synergizes with AML therapies. S4. ULK1 inhibition changes signaling in AML cells. S5. ULK1 inhibition hampers ROS. S6. ULK1 inhibition accumulates dysfunctional mitochondria. S7. ULK1 inhibition impairs colony forming ability and delays leukemia progression. S8. In vitro and in vivo synergy of ULK1 inhibition with AML therapies.

  • Open Access

    Supplementary Figures 1-8 from Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) Overcomes Adaptive Drug Resistance in Acute Myelogenous Leukemia

    by Seemana Bhattacharya, Sujan Piya, Huaxian Ma, Priyanka Sharma, Qi Zhang, Natalia Baran, Vivian R. Ruvolo, Teresa McQueen, R. Eric Davis, Rasoul Pourebrahim, et al.

    S1. Effect of genetic abrogation of ULK1 in vitro and in vivo. S2. ULK1 inhibitor SBI-0206965 has anti-leukemic activity and can overcome autophagic adaptation in drug-resistant cells. S3. ULK1 inhibition reverses drug-resistance and synergizes with AML therapies. S4. ULK1 inhibition changes signaling in AML cells. S5. ULK1 inhibition hampers ROS. S6. ULK1 inhibition accumulates dysfunctional mitochondria. S7. ULK1 inhibition impairs colony forming ability and delays leukemia progression. S8. In vitro and in vivo synergy of ULK1 inhibition with AML therapies.